Generic Name and Formulations:
Trifluridine 1%; oph. soln; contains thimerosal.
Indications for VIROPTIC:
Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex types 1 and 2.
Adults and Children:
<6yrs: not recommended. Do not exceed recommended dose. ≥6yrs: 1 drop every 2hrs while awake; max 9 drops/day. After reepithelialization, 1 drop every 4hrs for 7 days (at least 5 drops/day); max 21 days therapy. Reevaluate if no improvement in 7 days or incomplete reepithelialization in 14 days.
Glaucoma. Pregnancy (Cat.C). Nursing mothers.
Transient ocular burning or stinging, keratopathy, edema, irritation, keratitis sicca, hyperemia, increased intraocular pressure.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC